AskBio Reels In $235M to Advance Gene Therapy Clinical Trials
Summary
Asklepios BioPharmaceutical (AskBio) has raised $235 million in financing to support its research and development of gene therapies for rare, genetic disorders. The funding came from TPG Capital and Vida Ventures, which together invested $225 million and gained a minority stake in the Research Triangle Park, NC, company. In 2014, Baxter (NYSE: BAX ) paid $70 million up front for Chatham Therapeutics, an AskBio spinout developing hemophilia gene therapies. AskBio’s current pipeline has experimental gene therapies for neuromuscular diseases, central nervous system disorders, and cardiovascular conditions. AskBio was founded in 2001 by Jude Samulski, the company’s president chief scientific officer, and CEO Sheila Mikhail, a veteran life sciences executive.
Classifications
AskAI Classifications
LabelsLinked Companies
